Doxorubicin
- Generic Name
- Doxorubicin
- Brand Names
- Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 23214-92-8
- Unique Ingredient Identifier
- 80168379AG
- Background
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...
- Indication
Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...
- Associated Conditions
- AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
- Associated Therapies
- -
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jennifer Crombie, MD
- Target Recruit Count
- 41
- Registration Number
- NCT05800366
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05774275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05766605
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05748834
- Locations
- 🇺🇸
Alliance Cancer Specialists, Bensalem, Pennsylvania, United States
🇺🇸Maryland Oncology Hematology, Columbia, Maryland, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05701436
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1122
- Registration Number
- NCT05691478
- Locations
- 🇺🇸
Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Conditions
- Interventions
- Procedure: Biospecimen CollectionBiological: Bleomycin SulfateProcedure: Computed TomographyDrug: Brentuximab VedotinDrug: DacarbazineDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingDrug: EtoposideProcedure: Positron Emission TomographyDrug: Etoposide PhosphateOther: Questionnaire AdministrationBiological: NivolumabDrug: Vinblastine SulfateRadiation: Involved-site Radiation TherapyDrug: PrednisoloneDrug: PrednisoneDrug: Procarbazine HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1875
- Registration Number
- NCT05675410
- Locations
- 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT05673785
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
🇨🇳The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, China
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 24
- Registration Number
- NCT05661201
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 139
- Registration Number
- NCT05645380
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.